Page last updated: 2024-10-20

pyridoxamine and Fatty Liver, Nonalcoholic

pyridoxamine has been researched along with Fatty Liver, Nonalcoholic in 2 studies

Research Excerpts

ExcerptRelevanceReference
"Pyridoxamine treatment was associated with increased levels of tumor necrosis factor alpha (TNF-α) mRNA transcripts in the liver."5.56Pyridoxamine improves metabolic and microcirculatory complications associated with nonalcoholic fatty liver disease. ( Daliry, A; Flores, EEI; Pereira, ENGDS; Rodrigues, KL; Silvares, RR, 2020)
"Pyridoxamine treatment was associated with increased levels of tumor necrosis factor alpha (TNF-α) mRNA transcripts in the liver."1.56Pyridoxamine improves metabolic and microcirculatory complications associated with nonalcoholic fatty liver disease. ( Daliry, A; Flores, EEI; Pereira, ENGDS; Rodrigues, KL; Silvares, RR, 2020)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Pereira, ENGDS1
Silvares, RR1
Flores, EEI1
Rodrigues, KL1
Daliry, A1
Gaens, KH1
Niessen, PM1
Rensen, SS1
Buurman, WA1
Greve, JW1
Driessen, A1
Wolfs, MG1
Hofker, MH1
Bloemen, JG1
Dejong, CH1
Stehouwer, CD1
Schalkwijk, CG1

Other Studies

2 other studies available for pyridoxamine and Fatty Liver, Nonalcoholic

ArticleYear
Pyridoxamine improves metabolic and microcirculatory complications associated with nonalcoholic fatty liver disease.
    Microcirculation (New York, N.Y. : 1994), 2020, Volume: 27, Issue:3

    Topics: Animals; Diet, High-Fat; Lipid Peroxidation; Liver; Male; Microcirculation; Non-alcoholic Fatty Live

2020
Endogenous formation of Nε-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis.
    Journal of hepatology, 2012, Volume: 56, Issue:3

    Topics: Aged; Biomarkers; Biopsy; Cytokines; Enzyme Inhibitors; Fatty Liver; Female; Gene Expression; Guanid

2012